

Results of a Phase 2 Randomized Withdrawal Study of Simufilam in Mild-to-moderate Alzheimer's Disease



Suzanne Hendrix, PhD, Pentara Corporation 2023 CTAD Alzheimer's Congress



Author List and Disclosures

Ian Cohen, Shishuka Malhotra, Paayal Patel, Craig Mallinckrodt, <u>Suzanne Hendrix</u>, Ben Murray, Leslie Jones, Antonio Hernandez, Emmalee Crow, Melissa A. Synder, Lindsay H. Burns, Jim Kupiec and Nadav Friedmann

- Simufilam is drug candidate under development by Cassava Sciences, Inc. (Austin, TX).
- Clinical research with simufilam is funded by Cassava Sciences.
- I. Cohen, S. Malhotra and P. Patel are clinical site investigators for simufilam.
- B. Murray, L. Jones, A. Hernandez, E. Crow, M. Snyder, L. Burns and J. Kupiec are employees and equity holders of Cassava Sciences, as was the late N. Friedmann.
- S. Hendrix and C. Mallinckrodt are employees of Pentara and contributed clinical data analysis for studies of simufilam with funding from Cassava Sciences.
- Simufilam benefits from scientific & financial support from the NIA (AG050301, AG056166, AG060878, AG065152, AG067972).





Forward-Looking Statements & Safe Harbor

Cassava Sciences, Inc. ("Company", "we", "our") is a publicly-traded company. This presentation contains forward-looking statements of the Company, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to: our strategy and plans; the design, scope, conduct, or intended purpose of our randomized withdrawal study or Phase 3 program of simufilam in patients with Alzheimer's disease; the ability of simufilam to provide patients with drug effects; the apparent ability of simufilam to favor patients with mild Alzheimer's disease; the safety or tolerance of simufilam in our clinical trials; the interpretation of clinical data generated in our open-label study or randomized withdrawal study; the treatment of Alzheimer's disease dementia; the safety or efficacy of simufilam in patients; verbal commentaries made by our employees; and potential benefits, if any, of the our product candidates. These statements may be identified by words such as "may," "anticipate," "believe," "could," "expect," "appear," "intend," "plan," "possible," "potential," and other words and terms of similar meaning.

Simufilam is an investigational product candidate. It is not approved by any regulatory authority. Its safety, efficacy or other desirable attributes have not been established in patients. All clinical data from our open-label study and randomized withdrawal study are inherently exploratory in nature and, as with all early clinical data, should be interpreted with caution. Data results from our open-label study or randomized withdrawal study do not constitute, and should not be interpreted as, clinical evidence of therapeutic safety or benefit for simufilam.

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in regulatory approval and subsequent commercialization of a product. In addition, our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.

Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits, if any, of simufilam in patients with Alzheimer's disease, any unanticipated impacts of national or world events on our business operations, including those described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this presentation. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at <u>www.sec.gov</u>.

This presentation contains statistical data and drug information based on the work of our independent consultants, industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such data or information. You are cautioned not to give undue weight to such data. The content of this presentation is solely our responsibility and does not represent the official views of the National Institutes of Health or any other government agency.





Simufilam Mechanism of Action

• Altered FLNA enables $A\beta_{42}$ signaling via two different receptors:


- 1) α 7-nicotinic acetylcholine receptor (α 7nAChR) \longrightarrow tau hyperphosphorylation
- 2) Toll-like receptor 4 (TLR4) ----- releases inflammatory cytokines
- Simufilam binds *altered* FLNA, restores its proper shape/function, potently suppressing $A\beta_{42}$ signaling via α 7nAChR and TLR4.
- Through a single target, simufilam reduces neurodegeneration and neuroinflammation.





Altered FLNA links to α7-nicotinic acetylcholine receptor

- Aβ₄₂ binds α7nAChR and recruits FLNA, altering its shape.
- Altered FLNA linkage to α 7nAChR enables a *femtomolar* affinity of A β_{42} for α 7nAChR and the signaling that hyperphosphorylates tau.






Altered FLNA links to α7-nicotinic acetylcholine receptor

- Aβ₄₂ binds α7nAChR and recruits FLNA, altering its shape.
- Altered FLNA linkage to α 7nAChR enables a *femtomolar* affinity of A β_{42} for α 7nAChR and the signaling that hyperphosphorylates tau.


Simufilam binds altered FLNA, disrupts its linkage to α 7nAChR, stops A β_{42} signaling and tau hyperphosphorylation.





Altered FLNA links to toll-like receptor 4 (TLR4)

- Altered FLNA linkage to TLR4 enables Aβ₄₂ to activate TLR4.
- Persistent TLR4 activation results in chronic neuroinflammation.




entara



Altered FLNA links to toll-like receptor 4 (TLR4)


- Altered FLNA linkage to TLR4 enables Aβ₄₂ to activate TLR4.
- Persistent TLR4 activation results in chronic neuroinflammation.

Simufilam binds altered FLNA, disrupts its linkage to TLR4, stops $A\beta_{42}$ -induced neuroinflammation.





Randomized Withdrawal (RW) Study Design



Full Analysis Set = 155 patients

- RW followed encouraging results in a 12-month open-label study.
- RW was designed to compare change in cognition over 6 months in AD patients who continue vs. those who discontinue simufilam.
- Any patient who completed 12-month open-label study was eligible to enroll in the RW.





Drug Safety

Adverse Events Observed in 12-month Open-label Study

	Occurrences	Patients N (%)
COVID-19	21	21 (9.5)
Urinary Tract Infection	23	20 (9.1)
Headache	22	17 (7.7)
Diarrhea	15	14 (6.4)
Hypertension	13	13 (5.9)
Insomnia	11	11 (5.0)
Dizziness	10	10 (4.5)
Fall	15	9 (4.1)
Depression	9	9 (4.1)
Nausea	9	8 (3.6)





Drug Safety

Adverse Events Observed in 6-month RW, ≥ 3 Occurrences

	Simufilam 100 mg (n=80)	Placebo (n=77)
Total number of AEs	77	92
COVID-19	5	4
Fall	1	4
Anxiety	2	2
Urinary Tract Infection	1	3
Hematuria	2	1
Headache	2	1





12-Month Open-label Period: Baseline Scores

	Mild (MMSE 21–30)	Moderate (MMSE 10–20)	
	N=133	N=83	
	ADAS	-Cog11	
Mean (SD)	15.0 (6.26)	25.7 (9.21)	
Min, Max	3.0, 33.3	4.7, 51.7	
	MM	SE	
Mean (SD)	23.8 (2.19)	17.8 (1.86)	
Min, Max	21, 30	10, 20	

<u>Note:</u> Patients in prior simufilam studies could enroll in the open-label study regardless of MMSE. New patients were MMSE 16–26, or > 26 with a prior positive amyloid PET scan. This resulted in MMSE range 10–30.





sciences

12-Month Open-label Period: Top-line Summary

- 47% of patients improved on ADAS-cog.
 - This group *improved* by a mean of 4.7 points.

An additional 23% of patients declined < 5 points on ADAS-cog.

• This group declined by a mean of 2.5 points.

Mild patients improved over 12 months.

- Mild patients *improved* by a mean of 0.73 points.
- Moderate patients declined by a mean of 4.11 points.








Simufilam vs. Historical Placebo in Mild-to-Moderate AD

Decline on ADAS-Cog, baseline to 12 months







Simufilam vs. Historical Placebo in Early or Mild AD

Change in ADAS-Cog, baseline to 12 months

	Study	N	Change	CI	\checkmark	Imp	orove	Decline	
	Early AD		<u>v</u>						
1	Aducanumab ENGAGE	545	3.39	(2.54,4.24)					
	Aducanumab EMERGE	548	3.41	(2.52,4.29)					
	Donanemab TRAILBLAZER-ALZ	90	3.15	(1.63,4.67)					
i C	Gantenerumab Phase 3	266	2.17	(0.95,3.39)				_	
ې م	Lecanemab 201	247	3.25	(1.45,5.05)					
	Lecanemab Clarity	859	3.7	(2.98,4.41)					
۵	Mild AD								
	Solanezumab Expedition 1 Mild	338	3.24	(1.79,4.68)				_	
	Solanezumab Expedition 2 Mild	325	3.37	(2.12,4.61)				_	
İ	Solanezumab Expedition 1&2 Mild	663	3.3	(2.35,4.25)					
۲	ADCS Studies Mild (Thomas 2016)	2539	3.07	(2.82,3.32)					
*	ADNI Mild (2022)	214	4.61	(2.97,6.25)					
*	ADNI Mild (Ito 2011)	186	3.66	(3.03,4.3)				_	
	Meta-analysis Mild (Ito 2010)	12303	3.89	(3.31,4.48)				_	
ſ	Simufilam Mild Active	133	-0.73	(-2.33,0.88)			-		
	* Observatio	nal studies	5		-3	-2	-1	0 1 2 3 4 5 6 Estimate	





Baseline Demographics in Randomized Withdrawal

	Simufilam	Placebo	
N (M,F)	39, 41	34, 43	
Mean Age (SD)	70.1 (8.3)	71.1 (7.9)	
White, non- Hispanic (N,%)	59, 73.7%	61, 79.2%	
Black (N,%)	1, 1.2%	1, 1.3%	
Pacific Islander / Hawaiian (N,%)	0, 0%	1, 1.3%	
Asian (N,%)	2, 2.5%	2, 2.6%	
Hispanic or Latino (N,%)	18, 22.5%	13, 16.9%	

CASSAVA



Randomized Withdrawal Baseline Scores


	Mild (MMS	SE 21 – 30)	Moderate (MMSE 4 – 20)		
	Placebo Simufilam N=36 N=39		Placebo N=41	Simufilam N=39	
		ADAS	-Cog11		
Mean (SD)	11.0 (5.25) 11.2 (5.73)		31.5 (12.83)	27.9 (11.73)	
Min, Max	2.7, 23.7	1.3, 28.3	12.0, 63.7	13.7, 56.0	
		MM	SE		
Mean (SD)	25.1 (2.53)25.3 (2.34)21, 3021, 30		14.4 (4.51)	15.2 (4.36)	
Min, Max			5, 20	4, 20	

<u>Note:</u> RW baseline follows the 12-month open-label study, which included some patients with baseline MMSE < 16 or > 26. MMSE range for the RW was 4–30.






Change in ADAS-Cog11 in RW: Full Analysis Set







Change in ADAS-Cog11 in RW: Mild AD Patients





* 100% slowing of decline + improvement



19

Change in ADAS-Cog11 in Randomized Withdrawal

	LS Mean Difference at Month 6 (SE)	Confidence Interval (95%)	Percent Slowing of Decline	P value
Full Analysis Set	-0.56 (0.786)	-2.12, 0.99	38%	0.476
Mild AD Patients (MMSE 21 – 30)	—1.13 (0.745)	-2.63, 0.37	205%	0.136
Moderate AD Patients (MMSE 4 – 20)	0.15 (1.343)	-2.54, 2.84	none	0.912


<u>Note:</u>

The moderate subgroup included severe patients in both treatment arms. Greater difficulty in treating moderate or severe AD is expected.





0-18 Months Change in ADAS-Cog11 in Mild vs. Moderate



sciences



Simufilam Mild vs. 18-month Early AD Historical Declines

			Change from Baseline		
Study	Treatment	MMSE Range	Estimate	CI	Decline
CLARITY	Placebo	22-30	5.61	(5.31, 5.91)	
EMERGE	Placebo	24-30	5.17	(4.76, 5.57)	
ENGAGE	Placebo	24-30	5.17	(4.80, 5.55)	
Trailblazer	Placebo	20-28	4.82	(4.17, 5.47)	_
PTI-125-04	Simufilam100mg-Simufilam100mg	21-26	0.11	(-1.30, 1.52)	_
PTI-125-04	Simufilam100mg-Placebo	21-26	0.76	(-0.81, 2.34)	_
					-1 0 1 2 3 4 5 6 Estimate

The narrow margin between patients on simufilam for 18 months and those on simufilam and switched to placebo after 12 months is consistent with disease-modifying drug effects.





Summary of Randomized Withdrawal Results

- Oral simufilam 100 mg appears safe and well-tolerated.
- Simufilam slowed cognitive decline by 38% on ADAS-Cog11 at 6 months vs. placebo (not statistically significant) in this study of mild-to-moderate AD.
- Simufilam appears to favor patients with mild AD.
 - In patients with mild AD, simufilam slowed cognitive decline by 205% on ADAS-Cog11 at 6 months vs. placebo (p = 0.14 with N=36 and 39 respectively).
 - In patients with mild AD, simufilam stabilized ADAS-Cog11 scores over 18 months.





Next Steps

- Oral simufilam is under clinical evaluation in two global, pivotal Phase 3 studies in a total of ~1,900 patients with mild-to-moderate AD dementia.
 - RETHINK-ALZ is a 12-month study.
 - REFOCUS-ALZ is an 18-month study.
- ~ 60-70% of patients entered Phase 3 with mild AD (MMSE 21-27).
- Both Phase 3 studies received a Special Protocol Assessment (SPA) from FDA.
- Completion of enrollment in the pivotal Phase 3 program is expected Q4 2023.







Thank you!

•Pentara